Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038657 | 0.86 | KDM4E (0.68) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL30603139 | 0.86 | KDM4E (0.68) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL2448633 | 0.86 | KDM4E (0.68) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL6778691 | 0.85 | APP (0.69) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL9641759 | 0.84 | KDM4E (0.65) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL12488031 | 0.84 | APP (0.70) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL29445571 | 0.84 | APP (0.70) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL106725 | 0.84 | APP (0.70) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL29365544 | 0.84 | APP (0.70) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A | |
| SCHEMBL29979287 | 0.84 | KDM4E (0.65) | KDM4EPHLPP2ADORA2ACYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225631-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6242459-B1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-06-05 | — | — | US | disclosed |
| EP-0979078-A4 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0979078-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998030218-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | CCR5, CCR2, CCR1 | KDM4E 4247/4885PHLPP2 2108/4885ADORA2A 116/4885 |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | PSEN1, PSEN2, SNCA | KDM4E 759/4885PHLPP2 279/4885ADORA2A 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.